Last reviewed · How we verify
Agonist GnRH; estradiol Valerate; progesterone
This combination suppresses endogenous gonadotropins via GnRH agonist while providing exogenous estradiol and progesterone to support the luteal phase during assisted reproductive cycles.
This combination suppresses endogenous gonadotropins via GnRH agonist while providing exogenous estradiol and progesterone to support the luteal phase during assisted reproductive cycles. Used for Assisted reproductive technology (ART) / in vitro fertilization (IVF) support, Controlled ovarian hyperstimulation in infertility treatment.
At a glance
| Generic name | Agonist GnRH; estradiol Valerate; progesterone |
|---|---|
| Also known as | Decapeptyl (IPSEN)3.75 mg., Progynova 1 mg (Bayer Schering Farma), Natural micronized progesterone 400 mg/12 hours |
| Sponsor | Instituto Valenciano de Infertilidad, IVI VALENCIA |
| Drug class | Hormone combination therapy; GnRH agonist with steroid hormones |
| Target | GnRH receptor; estrogen receptor; progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
The GnRH agonist downregulates the pituitary to prevent premature luteinizing hormone (LH) surge during controlled ovarian hyperstimulation. Estradiol valerate and progesterone are then administered exogenously to mimic natural hormone levels and support endometrial development and embryo implantation during in vitro fertilization (IVF) protocols.
Approved indications
- Assisted reproductive technology (ART) / in vitro fertilization (IVF) support
- Controlled ovarian hyperstimulation in infertility treatment
Common side effects
- Headache
- Hot flashes
- Injection site reactions
- Mood changes
- Breast tenderness
- Ovarian hyperstimulation syndrome (OHSS)
Key clinical trials
- Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients (NA)
- The Role of Hormones in Postpartum Mood Disorders (PHASE2)
- IVM - Fresh ET (THE SAIGON PROTOCOL) Versus IVF - FET in PCOS Women (NA)
- Adaptions and Resiliency to Multi-Stressor OpeRations (PHASE4)
- The Impact of Endometrial Compaction on Assisted Reproductive Technology Outcome
- Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol (NA)
- A Treatment Study for Premenstrual Syndrome (PMS) (PHASE1)
- The Effects of Reproductive Hormones on Mood and Behavior (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: